Early diagnosis and the optimal control of inflammation, with a continuous cycle of
assessment, treatment, monitoring, and adjustment of therapy, is best practice for the …

Background In asymptomatic patients with inflammatory bowel disease (IBD),“monitoring”
involves repeated testing aimed at early recognition of disease exacerbation. We aimed to …

Summary The coronavirus disease 2019 (COVID-19) pandemic is changing the
management of many chronic diseases, including that of patients with inflammatory bowel …

Inflammatory bowel disease (IBD) denotes a group of chronic incurable disorders
characterized by relapsing-remitting inflammation of the gastrointestinal tract. IBD represents …

Background Mucosal healing (MH) is currently accepted as one of the best treatment targets
in Crohn's disease. However, even in patients with sustained MH, residual bowel wall …

Background Colonoscopy [CS] is the standard for assessing disease activity in ulcerative
colitis [UC], although invasive and poorly tolerated. Bowel ultrasound [BUS] may be a valid …

Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

Effective prevention and management of osteoporosis would require suitable methods for
population screenings and early diagnosis. Current clinically-available diagnostic methods …

Objective IBD therapies and treatments are evolving to deeper levels of remission.
Molecular measures of disease may augment current endpoints including the potential for …

Introduction Etrolizumab is a next-generation anti-integrin with dual action that targets two
pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis …